SYRS - Syros Pharmaceuticals Short-Term Debt to Capital

This daily price chart for Syros Pharmaceuticals (SYRS) illustrates metrics where the value is 0.00. The business focuses on drug development through the study of gene activity, enabling the global scaling of proprietary solutions with high profitability. Revenue is generated through the implementation of leukemia therapies. However, stringent regulatory requirements and trial failures have weakened defensive barriers, necessitating an update to the research strategy.

To assess the fundamental stability of Syros Pharmaceuticals (SYRS), which develops precision leukemia therapies, the dynamics of short-term debt relative to equity are critical, as the ratio of liabilities maturing within one year to capital reveals the risk of cash flow gaps, allowing investors to determine whether the biotech startup's balance sheet is overburdened by short-term debt during costly clinical trials.